Candidozyma auris, a fungal pathogen with a bloodstream infection mortality rate of 45 percent, evades standard hospital treatments by copying its entire genome under drug pressure, according to a study published in Nature Communications and detailed by WELT.
In Plain English: The Clinical Takeaway
- Genomic Duplication: The fungus survives standard antifungal medications by making extra copies of its entire DNA set, drastically increasing its chances of mutating to resist drugs.
- Hospital Persistence: The pathogen clings tightly to patient skin and medical equipment, spreading easily between vulnerable individuals in intensive care units.
- High Mortality: When the organism breaches the bloodstream of a critically ill patient, the resulting infection carries a 45 percent fatality rate.
Genetic Plasticity Under Drug Pressure
The research team led by Hugh Gifford at the University of Exeter investigated why two critically ill patients failed to respond to echinocandins, the primary class of medications used to destroy fungal cell walls during severe infections. Previous clinical observations linked resistance in this pathogen primarily to alterations in the genes FKS1 and FKS2, yet sequencing revealed no such changes in these clinical samples. An accidental laboratory over-cultivation of the pathogen plates alongside the antifungal drug anidulafungin revealed that a tiny fraction of cells continued to multiply over several days, producing both slow-growing small colonies and faster-growing large variants.
Further analysis showed that the rapidly expanding cells carried significantly more mutations in the gene Crazy-one (CRZ1), which governs cell wall stability and remodeling, than the baseline isolates. The researchers concluded that resistance builds gradually through an initial phase of drug tolerance followed by massive genomic duplication and targeted mutations. „Unsere Entdeckung bedeutet, dass wir nun nach neuen Wegen suchen müssen, um Patienten zu behandeln und diesen tödlichen Pilz aus Krankenhäusern zu beseitigen“, the researchers stated, noting plans to test combination therapies involving multiple antifungals.”
Global Spread and German Public Health Impact
Originally identified in Japan in 2009 under its former designation Candida auris, the pathogen has since caused outbreaks across more than 60 countries on every continent, earning a high-priority pathogen classification from the World Health Organization. According to data from the European Centre for Disease Prevention and Control, Germany ranks among the European nations registering substantial case numbers. Oliver Kurzai, head of the National Reference Center for Invasive Mycoses at the University of Würzburg, who was not involved in the British study, reported that Germany experiences a relatively stable baseline of roughly 100 initial detections annually, accompanied by a mandatory notification requirement for laboratory findings. Kurzai warned that ongoing regional expansion in Southern Europe increases the likelihood of imported cases, though echinocandin resistance currently remains rare in Germany at under five percent of isolated strains.
| Pathogen Strain | Primary Clinical Site | Systemic Mortality Rate | German Surveillance Status |
|---|---|---|---|
| Candidozyma auris | Bloodstream, Skin, Medical Devices | 45 percent | Mandatory notification (~100 cases/year) |
| Cladophialophora bantiana | Brain Abscesses | 60 to 70 percent | Rare; not systematically tracked |
Emerging Concerns With Invasive Mold Infections
Parallel clinical data from the United States Centers for Disease Control and Prevention highlight an accelerating trend involving another dangerous fungus, Cladophialophora bantiana. Clinical laboratory detections of this mold quadrupled from 2023 to 2025 from a low baseline, with infections leading to cerebral abscesses and carrying a fatality rate between 60 and 70 percent. While German infections involving this specific mold remain a clinical rarity without systematic national tracking, experts point to climate factors such as warming temperatures and extended droughts as plausible drivers that enhance the airborne spread of fungal spores via dust and soil, though direct causal proof remains under investigation.
Contraindications & When to Consult a Doctor
Hospitalized patients on intensive care units who exhibit unexplained fevers, systemic inflammatory response syndrome, or failure to respond to broad-spectrum antimicrobials require immediate diagnostic screening. Attending physicians must isolate colonized patients and evaluate treatment regimens using established susceptibility testing before modifying first-line echinocandin protocols.
The study uncovering the genomic duplication mechanism behind Candidozyma auris drug resistance was published in Nature Communications.
